We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PROT Animal Studies Confirms Potential Use of UMK-121
Product News

PROT Animal Studies Confirms Potential Use of UMK-121

PROT Animal Studies Confirms Potential Use of UMK-121
Product News

PROT Animal Studies Confirms Potential Use of UMK-121


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "PROT Animal Studies Confirms Potential Use of UMK-121"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Proteonomix, Inc. has announced the results of animal studies involving the Company's UMK-121 technology.

The pre-clinical studies were conducted in rodents and a large animal model to confirm the potential of the UMK-121 technology to mobilize Stromal Stem Cells ("SSCs") into the peripheral blood of animals, thereby making the SSCs available for therapeutic uses.

Ian McNiece, Proteonomix, Inc.'s Chief Scientific Officer, commented, "We continue to move forward building upon our existing scientific foundation. These tests provide us the first pre-clinical evidence of the potential viability of the UMK-121 technology. Further studies are planned to evaluate this approach in a model of tissue injury."

He continued, "We continue to focus on our goal of initiating human clinical trials to demonstrate the efficacy of our stem cell products in various applications of regenerative medicine. Our ongoing progress in manufacturing has enabled the company to expand its intellectual property portfolio and will help establish the company as a key emerging player in the dynamic stem cell field."

Michael Cohen, President of the Company, added, "We look forward to our initial human clinical trial of the UMK-121 technology in the near future and have a strong belief that the results of that trial will catapult Proteonomix into the forefront of the plethora of development stage companies with stem cell technologies. Our initial target will be End Stage Liver Disease ("ESLD") patients.”

Cohen continued, “According to Organ Donation and Transplantation ("NWHIC") over 60,000 Americans suffer from End Stage Liver Disease ("ESLD"). If successful, UMK-121 promises to revolutionize the current modality of treatment for these patients. Further, the Company is exploring partnership and joint venture opportunities in order to develop its portfolio of intellectual properties ("IP"), including but not limited to its Cosmeceutical, Diabetes and Cardiac IP."

Advertisement